Victory Capital Management Inc. reduced its holdings in shares of Celyad SA (NASDAQ:CYAD) by 12.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 325,312 shares of the company’s stock after selling 47,280 shares during the period. Victory Capital Management Inc. owned about 3.42% of Celyad SA worth $18,217,000 at the end of the most recent quarter.

Shares of Celyad SA (NASDAQ:CYAD) opened at $53.49 on Monday. Celyad SA has a 1 year low of $16.73 and a 1 year high of $64.75.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.watchlistnews.com/victory-capital-management-inc-has-18-22-million-stake-in-celyad-sa-cyad/1699736.html.

Separately, Piper Jaffray Companies reissued a “buy” rating and set a $49.00 price target (up from $35.00) on shares of Celyad SA in a research note on Friday, September 1st.

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Want to see what other hedge funds are holding CYAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celyad SA (NASDAQ:CYAD).

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with Analyst Ratings Network's FREE daily email newsletter.